Supernus Pharmaceuticals, Inc. (SUPN)
-NasdaqGM 6.55 
0.05(0.76%) 1:36PM EDT - Nasdaq Real Time Price
| Prev Close: | 6.60 |
|---|
| Open: | 6.38 |
|---|
| Bid: | 6.54 x 1200 |
|---|
| Ask: | 6.55 x 800 |
|---|
| 1y Target Est: | 11.80 |
|---|
| Beta: | 4.434 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 6.20 - 6.66 |
|---|
| 52wk Range: | 4.30 - 16.68 |
|---|
| Volume: | 622,227 |
|---|
| Avg Vol (3m): | 526,387 |
|---|
| Market Cap: | 202.23M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -2.26 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- SUPERNUS PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Tue, May 21)
- Supernus to Present at Two Investor ConferencesGlobeNewswire(Mon, May 20)
- SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Mon, May 20)
- 5 Stocks Setting Up to Break Outat TheStreet(Fri, May 17)
- SUPERNUS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 15)
- 8 Stocks Under $10 Trending Sharply Higherat TheStreet(Tue, May 14)
- Narrower-than-Expected Loss at SupernusZacks(Tue, May 14)
- Supernus Pharmaceuticals Reports First Quarter 2013 Financial ResultsGlobeNewswire(Mon, May 13)
- SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementsEDGAR Online(Mon, May 13)
- Q1 2013 Supernus Pharmaceuticals Earnings Release - After Market CloseCCBN(Mon, May 13)
- SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct FinEDGAR Online(Thu, May 9)
- Supernus Announces First Quarter 2013 Earnings Conference Call and WebcastGlobeNewswire(Mon, May 6)
- SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Mon, May 6)
- Supernus Announces Closing of $90 Million of 7.50% Convertible Senior Secured Notes Due 2019GlobeNewswire(Mon, May 6)
- Supernus Secures Financing For CNS Pipeline Developmentat Seeking Alpha(Sun, May 5)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 143.60 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -2.46 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.68 |
|---|
| Mean Recommendation*: | 1.7 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing products for the treatment of central nervous system diseases.
View More